Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect persistent activation of the androgen receptor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Stein, Mark N, Patel, Neal, Bershadskiy, Alexander, Sokoloff, Alisa, Singer, Eric A
Format: Artigo
Jezik:Inglês
Izdano: Medknow Publications & Media Pvt Ltd 2014
Teme:
Invited Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4023364/
https://ncbi.nlm.nih.gov/pubmed/24759590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.129133
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki